In Reply

Publisher Website

1 September 2007

journal article
other
Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology

Vol. 25 (25) , 4021-4023
https://doi.org/10.1200/jco.2007.11.4363

Abstract

No abstract available

This publication has 6 references indexed in Scilit:

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
The Lancet, 2007
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine, 2005
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* Study
Histopathology, 2003
HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization
Mayo Clinic Proceedings, 2002
Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
Journal of Clinical Oncology, 2001